Southern Endocrinology Associates

Mesquite, Texas 75149

6 studies enrolling now · 36 studies all time

What they study most

Atherosclerosis, Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease (ASCVD), Cardiovascular Diseases, Chronic Kidney Disease, Chronic Kidney Disease (CKD), Diabetes, Diabetes Mellitus, Type 2, Elevated Lp(a), Hypertension, Hypertriglyceridemia, Metabolic Dysfunction-Associated Steatotic Liver Disease

Studies at this site

• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Recruiting now
• A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide — Recruiting now
• A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes — Recruiting now
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) — Recruiting now
• A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia — Recruiting now
• A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes — Recruiting now
• A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease — Completed
• A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) — Running, not enrolling
• Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) — Running, not enrolling
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) — Running, not enrolling
• A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin — Running, not enrolling
• A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes — Completed
• A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN) — Completed
• A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia — Completed
• A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk — Completed
• Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) — Running, not enrolling
• A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities — Completed
• A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity — Running, not enrolling
• A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity — Running, not enrolling
• A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight — Running, not enrolling
• A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia — Completed
• A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity — Running, not enrolling
• CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) — Running, not enrolling
• A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities — Completed
• A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia — Completed
• A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin — Completed
• A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) — Completed
• A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight — Completed
• A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy — Completed
• A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin — Completed
• A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time — Completed
• A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program — Completed
• A Study of LY3437943 in Participants Who Have Obesity or Are Overweight — Completed
• A Study of LY3437943 in Participants With Type 2 Diabetes — Completed
• A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus — Completed
• A Study of LY3209590 in Participants With Type 1 Diabetes — Completed